荣昌生物(688331) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of 171,540.42 million yuan, a year-on-year increase of 58.40%[3] - The net profit attributable to the parent company was -146,786.25 million yuan, with a decrease in net profit excluding non-recurring gains and losses of -150,039.33 million yuan[5] - The basic earnings per share were -2.73 yuan, showing a slight improvement from -2.80 yuan in the previous year[3] - The weighted average return on net assets decreased to -54.06%, compared to -35.52% in the previous year[3] - The company expects a net loss for 2024, but with a trend towards reduced losses compared to the previous year[5] Assets and Equity - Total assets at the end of the reporting period were 549,914.78 million yuan, a decrease of 0.53% from the beginning of the period[4] - The equity attributable to the parent company decreased by 42.21% to 198,638.60 million yuan[4] Sales and Revenue Growth - The company reported a significant increase in sales revenue from innovative drugs, particularly from Tai Tasi Pi and Vidi Xi Tuo Monoclonal Antibody[7] - The gross profit margin of products continued to grow, while the sales expense ratio significantly decreased[5] Research and Development - The company is in the process of advancing multiple innovative drug candidates in critical trial phases, leading to increased R&D investment[5]